DOI QR코드

DOI QR Code

Population-based Cervical Cancer Screening Using High-risk HPV DNA Test and Liquid-based Cytology in Northern Thailand

  • Siriaunkgul, Sumalee (Department of Pathology, Faculty of Medicine, Chiang Mai University) ;
  • Settakorn, Jongkolnee (Department of Pathology, Faculty of Medicine, Chiang Mai University) ;
  • Sukpan, Kornkanok (Department of Pathology, Faculty of Medicine, Chiang Mai University) ;
  • Srisomboon, Jatupol (Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University) ;
  • Suprasert, Prapaporn (Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University) ;
  • Kasatpibal, Nongyao (Faculty of Nursing, Chiang Mai University) ;
  • Khunamornpong, Surapan (Department of Pathology, Faculty of Medicine, Chiang Mai University)
  • Published : 2014.08.30

Abstract

Background: Northern Thailand is a region with a high cervical cancer incidence. Combined high-risk HPV (hrHPV) DNA testing and cytology (co-testing) has increasingly gained acceptance for cervical cancer screening. However, to our knowledge, data from a population-based screening using co-testing have not been available in this region. This study therefore aimed to evaluate the performance of cytology and hrHPV test in women in northern Thailand. Materials and Methods: Cervical samples were collected for hybrid capture 2 (HC2) testing and liquid-based cytology from women aged 30 to 60 years who were residents in 3 prefectures of Chiang Mai in northern Thailand between May and September 2011. Women with positive cytology were referred to colposcopy, while women with positive for HC2 only were followed for 2 years. Results: Of 2,752 women included in this study, 3.0% were positive in both tests, 4.1% for HC2 only, and 1.3% had positive cytology only. At baseline screening, positive HC2 was observed in 70.6% among cytology-positive women compared with 4.3% among cytology-negative women. The prevalence of positive HC2 or cytology peaked in the age group 35-39 years and was lowest in the age group 55-60 years. High-grade squamous intraepithelial lesion or worse lesions (HSIL+) were histologically detected in 23.5% of women with positive baseline cytology and in 9.8% of women with positive baseline HC2 only on follow-up. All women with histologic HSIL+ had positive baseline HC2. Conclusions: The hrHPV test is superior to cytology in the early detection of high-grade cervical epithelial lesions. In this study, the prevalence of histologic HSIL+ on follow-up of women with positive hrHPV test was rather high, and these women should be kept under careful surveillance. In northern Thailand, hrHPV testing has a potential to be used as a primary screening test for cervical cancer with cytology applied as a triage test.

Keywords

Cervical cancer screening;liquid-based cytology;HPV DNA test;Thailand

References

  1. Arbyn M, Benoy I, Simoens C, et al (2009). Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev, 18, 321-30. https://doi.org/10.1158/1055-9965.EPI-08-0510
  2. Arbyn M, Ronco G, Anttila A, et al (2012). Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine, 30, 88-99. https://doi.org/10.1016/j.vaccine.2012.06.095
  3. Bulkmans NW, Berkhof J, Rozendaal L, et al (2007). Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year followup of a randomised controlled implementation trial. Lancet, 370, 1764-72. https://doi.org/10.1016/S0140-6736(07)61450-0
  4. Carestiato FN, Silva KC, Dimetz T, Oliveira LH, Cavalcanti SM (2006). Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay. Braz J Infect Dis, 10, 331-6.
  5. Castle PE, de Sanjose S, Qiao YL, et al (2012). Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine, 30, 117-22. https://doi.org/10.1016/j.vaccine.2012.05.071
  6. Castle PE, Fetterman B, Poitras N, et al (2009). Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol, 113, 595-600. https://doi.org/10.1097/AOG.0b013e3181996ffa
  7. Curado MP, Edwards B, Shin HR, et al (2007). Cancer incidence in five continents, Vol. IX. Lyon: IARC Scientific Publications No.160.
  8. Cuzick J, Clavel C, Petry KU, et al (2006). Overview of the european and north american studies on HPV testing in primary cervical cancer screening. Int J Cancer, 119, 1095-101. https://doi.org/10.1002/ijc.21955
  9. Cuzick J, Szarewski A, Cubie H, et al (2003). Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet, 362, 1871-6. https://doi.org/10.1016/S0140-6736(03)14955-0
  10. Dudding N, Crossley J (2013). Sensitivity and specificity of HPV testing: what are the facts? Cytopathology, 24, 283-8.
  11. Ferreccio C, Barriga MI, Lagos M, et al (2013). Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. Int J Cancer, 132, 916-23. https://doi.org/10.1002/ijc.27662
  12. Franceschi S, Herrero R, Clifford GM, et al (2006). Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer, 119, 2677-84. https://doi.org/10.1002/ijc.22241
  13. Herrero R, Hildesheim A, Bratti C, et al (2000). Populationbased study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst, 92, 464-74. https://doi.org/10.1093/jnci/92.6.464
  14. Ito K, Tsunematsu M, Satoh K, Kakehashi M, Nagata Y (2013). Effectiveness of cervical cancer screening based on a mathematical screening model using data from the Hiroshima Prefecture Cancer Registry. Asian Pac J Cancer Prev, 14, 4897-902. https://doi.org/10.7314/APJCP.2013.14.8.4897
  15. Jin XW, Lipold L, McKenzie M, Sikon A (2013). Cervical cancer screening: what's new and what's coming? Cleve Clin J Med, 80, 153-60. https://doi.org/10.3949/ccjm.80a.12092
  16. Junyangdikul P, Tanchotsrinon W, Chansaenroj J, et al (2013). Clinical prediction based on HPV DNA testing by hybrid capture 2 (HC2) in combination with liquid-based cytology (LBC). Asian Pac J Cancer Prev, 14, 903-7. https://doi.org/10.7314/APJCP.2013.14.2.903
  17. Kantathavorn N, Kietpeerakool C, Suprasert P, et al (2008). Clinical relevance of atypical squamous cells of undetermined significance by the 2001 bethesda system: experience from a cervical cancer high incidence region. Asian Pac J Cancer Prev, 9, 785-8.
  18. Katki HA, Schiffman M, Castle PE, et al (2013). Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis, 17, 56-63. https://doi.org/10.1097/LGT.0b013e318285437b
  19. Kiatiyosnusorn R, Suprasert P, Srisomboon J, et al (2010). Highgrade histologic lesions in women with low-grade squamous intraepithelial lesion cytology from a region of Thailand with a high incidence of cervical cancer. Int J Gynaecol Obstet, 110, 133-6. https://doi.org/10.1016/j.ijgo.2010.03.022
  20. Leinonen M, Kotaniemi-Talonen L, Anttila A, et al (2008). Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer, 123, 1344-9. https://doi.org/10.1002/ijc.23670
  21. Li J, Huang R, Schmidt JE, Qiao YL (2013). Epidemiological features of human papillomavirus (HPV) infection among women living in mainland China. Asian Pac J Cancer Prev, 14, 4015-23. https://doi.org/10.7314/APJCP.2013.14.7.4015
  22. Massad LS, Einstein MH, Huh WK, et al (2013). 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis, 17, 1-27.
  23. Ogilvie GS, Krajden M, van Niekerk DJ, et al (2012). Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study. Br J Cancer, 107, 1917-24. https://doi.org/10.1038/bjc.2012.489
  24. Othman N, Othman NH (2014). Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation. Asian Pac J Cancer Prev, 15, 2245-9. https://doi.org/10.7314/APJCP.2014.15.5.2245
  25. Pan QJ, Hu SY, Zhang X, et al (2013). Pooled analysis of the performance of liquid-based cytology in populationbased cervical cancer screening studies in china. Cancer Cytopathol, 121, 473-82. https://doi.org/10.1002/cncy.21297
  26. Pandey S, Mishra M, Chandrawati (2012). Human papillomavirus screening in north Indian women. Asian Pac J Cancer Prev, 13, 2643-6. https://doi.org/10.7314/APJCP.2012.13.6.2643
  27. Rai AK, Das D, Kataki AC, et al (2014). Hybrid capture 2 assay based evaluation of high-risk HPV status in healthy women of north-east India. Asian Pac J Cancer Prev, 15, 861-5. https://doi.org/10.7314/APJCP.2014.15.2.861
  28. Rashid RM, Dahlui M, Mohamed M, Gertig D (2013). Adapting the Australian system: is an organized screening program feasible in Malaysia?--an overview of cervical cancer screening in both countries. Asian Pac J Cancer Prev, 14, 2141-6. https://doi.org/10.7314/APJCP.2013.14.3.2141
  29. Ronco G, Giorgi-Rossi P, Carozzi F, et al (2006). Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol, 7, 547-55. https://doi.org/10.1016/S1470-2045(06)70731-8
  30. Ronco G, Segnan N, Giorgi-Rossi P, et al (2006). Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst, 98, 765-74. https://doi.org/10.1093/jnci/djj209
  31. Sankaranarayanan R, Nene BM, Shastri SS, et al (2009). HPV screening for cervical cancer in rural india. N Engl J Med, 360, 1385-94. https://doi.org/10.1056/NEJMoa0808516
  32. Sharma M, Bruni L, Diaz M, et al (2013). Using HPV prevalence to predict cervical cancer incidence. Int J Cancer, 132, 1895-900. https://doi.org/10.1002/ijc.27835
  33. Sukvirach S, Smith JS, Tunsakul S, et al (2003). Populationbased human papillomavirus prevalence in lampang and Songkla, thailand. J Infect Dis, 187, 1246-56. https://doi.org/10.1086/373901
  34. Swangvaree SS, Kongkaew P, Rugsuj P, Saruk O (2010). Prevalence of high-risk human papillomavirus infection and cytologic results in Thailand. Asian Pac J Cancer Prev, 11, 1465-8.
  35. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  36. Wang Y, Yu YH, Shen K, et al (2014). Cervical cancer screening and analysis of potential risk factors in 43,567 women in Zhongshan, China. Asian Pac J Cancer Prev, 15, 671-6. https://doi.org/10.7314/APJCP.2014.15.2.671
  37. Zhao FH, Lin MJ, Chen F, et al (2010). Performance of highrisk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from china. Lancet Oncol, 11, 1160-71. https://doi.org/10.1016/S1470-2045(10)70256-4
  38. Zorzi M, Del Mistro A, Farruggio A, et al (2013). Use of a highrisk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG, 120, 1260-7. https://doi.org/10.1111/1471-0528.12272

Cited by

  1. Performance of HPV DNA Testing with Hybrid Capture 2 in Triaging Women with Minor Cervical Cytologic Abnormalities (ASC-US/LSIL) in Northern Thailand vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10961
  2. Value of PAX1 Methylation Analysis by MS-HRM in the Triage of Atypical Squamous Cells of Undetermined Significance vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5843
  3. Application of HPV DNA Testing in Follow-up after Loop Electrosurgical Excision Procedures in Northern Thailand vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6093
  4. Manual Liquid Based Cytology for Pap Smear Preparation and HPV Detection by PCR in Pakistan vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.579
  5. High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand vol.88, pp.1, 2015, https://doi.org/10.1002/jmv.24290
  6. Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand vol.11, pp.6, 2016, https://doi.org/10.1371/journal.pone.0158184
  7. Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis vol.94, pp.6, 2018, https://doi.org/10.1136/sextrans-2017-053412